




Stem Med
PRIVATE LIMITED
Tree of life

Stem Med Update

24th April 2018

“This presentation contains certain financial information and results of operation, and may also contain certain projections, plans, strategies, and objectives of the Company which are not statements of historical fact but would constitute “forward-looking statements” that reflect the Company’s current views with respect to future events and financial performance. These views expressed herein are based on a number of estimates and current assumptions which are subject to business, economic and political uncertainties and contingencies, as well as various risks which are in many cases outside the control of the Company, and which may change over time and may cause the Company’s future results to be materially different than expected or indicated by such statements. No assurance can be given that future events will occur, that projections will be achieved, or that the Company’s assumptions are correct. Such forward-looking statements are not guarantees of future performance and accordingly, the actual results, financial condition, performance or achievements of the Company may differ materially from those anticipated by the Company in the forward-looking statements. The information contained herein is current only as of its date and shall not, under any circumstances, create any implication that such information is correct as of any time subsequent to the date hereof or that there has been no change in the financial condition or affairs of the Company since such date. Opinions expressed herein reflect the judgment of the Company as of the date of this presentation and may be subject to change. This presentation may be updated from time to time and there is no undertaking by the Company to post any such amendments or supplements to this presentation. The Company will not be responsible for any consequences resulting from the use of this presentation, nor any undue reliance placed upon any opinion or statement contained herein.”

Stem Med





Present Facilities & Accreditation

- **Stem Med Cellular Laboratory** is equipped with ISO Class 5 cleanroom laboratory to perform sophisticated cell culturing.
- Licensed by *Ministry of Health (MOH), Singapore* to process, cryopreserve and store Bone Marrow, Peripheral Blood Stem Cells

MINISTRY OF HEALTH
Singapore

LICENSE
UNDER THE PRIVATE HOSPITALS AND
MEDICAL CLINICS ACT (CHAPTER 248)

This licence No. 15I0220/02/172 is issued to

Dr LIM ZI-YI
(licensee)

to operate a Clinical Laboratory

at 100 PASIR PANJANG ROAD # 03 - 05
(ADDRESS)
Singapore 118518

known as STEM MED CELLULAR LABORATORY
(Name of premises)

subject to the provisions of the Private Hospitals and Medical Clinics Act, the Regulations made thereunder and the terms and conditions stipulated by the Director of Medical Services.

This licence takes effect for a period of two years from 29/06/2017 to 28/06/2019 unless revoked under the provisions of the Act.

Director of Medical Services
Singapore

This is a computer generated document, no signature is required



Stem Med



Adult
Stem Cell
Banking

CellVec
Advanced
Therapy
Unit


Regenerative
Medicine

Adult Stem Cell Bank


- Storing Adult Blood and Bone Marrow
- Supports Parkway Cancer Centre Bone Marrow Transplant Centre

(Largest Private Transplant Service in the region)

Stem Med



Potential of Stem Cells Therapies




Clinical Research and Treatment Program



- Phase I/II clinical trial in Singapore opened 2018
Mesenchymal Stem Cell Therapy for Liver Cirrhosis
- Further studies on joints and neurological indications
in development
- Collaboration with regional centers for cellular therapy

Stem Med



The Cellular and Gene therapy division termed CellVec was established in Q1 2017

FDA Approves First CAR T-cell Therapy

Posted on August 31, 2017 by **Karen Honey, PhD**

Yesterday marked a much anticipated milestone for the oncology community: The U.S. Food and Drug Administration (FDA) **announced** the first approval of a type of immunotherapy known as CAR T-cell therapy.



Cost per therapy
\$450,000 USD

Gene and Cellular Therapy





Rapid rise in gene and cellular therapies FDA approved for clinical use

New and booming era of cell therapy manufacturing – **(est 17% year on year global growth with market value of >\$1 billion USD by 2022)**

Viral vectors form basis of many of the cell and gene therapies – but production is labour intensive and costly

CellVec Solution



CellVec specialises in the design and manufacture of viral vectors for gene modified cellular therapy

CellVec - Strategic Advantage

Location : Singapore – biotech centre, manufacturing reputation, strong regulatory and IP protection

Expertise : World-class scientific team, strong academic and industrial collaborations

Timing : World-wide boom in gene and cellular therapy, bottlenecks in viral vector manufacturing, opportunities to disrupt technology and be market leader

CellVec Advanced Therapy Unit

First in region high specification GMP Lab due to be completed end Q4 2018

To start producing clinical grade products early Q2 2019

Once fully operational in 2019/2020 – capacity to produce 25+ batches of viral vector/year

Current global commercial manufacturing price per batch : SGD \$700,000-1,000,000/batch

Thank You



Stem Med

PRIVATE LIMITED

Tree of life